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that epigenetic states and thereby tran-
scriptomes are altered in a directed and
heritable way. The work presents an
interesting example of the Lamarckian
paradigm (Martienssen, 2008; Koonin
and Wolf, 2009), in which the environ-
ment directs evolution, and induced
changes in the epigenetic state may in
turn create variations in gene expression
to be explored, selected for, and co-
opted through the generations.REFERENCES
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The discovery of a small-molecule allosteric inhibitor of the CDC34 ubiquitin-conjugating enzyme
(E2) by Ceccarelli et al. raises the possibility that it will be generally feasible to selectively inhibit
ubiquitin transfer at this central step in the ubiquitin pathway.There is significant interest in targeting
the ubiquitin proteasome system (UPS)
with small molecules for treatment of
diseases such as cancer and neurode-
generation (Bedford et al., 2011). In this
pathway, ubiquitin is transferred to sub-
strates through cycles of an E1-activating
enzyme-E2-conjugating enzyme-E3 ubiq-
uitin ligase cascade, leading to produc-
tion of a polyubiquitin chain covalently
attached to the substrate that targets it
for rapid degradation by the proteasome
(Figure 1A). Though molecules targeting
theE1 class of enzymes aswell as the pro-
teasomeare already in the clinic or in trials,
the development of inhibitors of compo-
nents in the middle of the pathway have
lagged behind. This is despite the fact
that E2s and E3s control the substrate
specificity and the type of ubiquitin linkage
formedand therefore potentially represent
more specific targets for small-molecule-
based therapy. In this issue of Cell, Cec-
carelli et al. (2011) report the identification
of the first inhibitor of an E2 enzyme, in thiscase the human E2 CDC34 (also called
UBE2R1), which plays a critical role in
the elimination of cell-cycle regulatory
proteins by the proteasome (Skaar and
Pagano, 2009). Unexpectedly, the inhib-
itor acts allosterically by binding to a
pocket distant from the active site. This
study indicates that it is possible to
develop a highly selective inhibitor of an
E2 enzyme and raises the possibility of
targeting other E2s in a similar manner.
The success of proteasome inhibitors
clinically has fueled the interest in devel-
oping inhibitors that block specific E1-
E2-E3 pathways (Bedford et al., 2011).
By targeting one or a small number of
E3-dependent processes, the effects on
overall protein homeostasis may be re-
stricted to the precise pathway intended.
CDC34 is one of approximately two dozen
ubiquitin E2s in mammals but is unique in
that it functions solely with one specific
class of E3s: the cullin-RING ligase (CRL).
Cullins employ a RING finger protein
(RBX1orRBX2), togetherwithaconservedpocket in cullins themselves, to recruit
ubiquitin-charged CDC34 (Deshaies and
Joazeiro, 2009; Kleiger et al., 2009). CRL
activity also requires modification of cullin
by the ubiquitin-like NEDD8 protein, a pro-
cess that is inhibited by a small-molecule
inhibitor of the neddylation E1 enzyme
(Figure 1B) (Bedford et al., 2011). As CRLs
are responsible for controlling the turnover
of cancer-relatedgenes, including thecell-
cycle inhibitor p27 (Skaar and Pagano,
2009), this class of E3s has received par-
ticular attention in cancer drug discovery.
To identify small-molecule inhibitors of
p27 ubiquitination, Ceccarelli et al. em-
ployed a fully reconstituted p27 ubiquiti-
nation reaction involving E1, CDC34, the
E3 CRL1SKP2-CKS1, and p27 in a high-
throughput screen, identifying CC0651
as a prime candidate for an inhibitor of
this pathway. Given the number of com-
ponents and thecomplexity of theprocess
being examined in this assay, CC0651
could block one of numerous steps. Using
a variety of related E3CRL complexes and5, June 24, 2011 ª2011 Elsevier Inc. 1007
Figure 1. Hierarchical Nature of the Ubiquitin-Proteasome System and Sites of Intervention
by Small Molecules
(A) Overview of the ubiquitin conjugation cascade showing the points at which Ubistatin, DBeQ, EerI, the
USP14 inhibitor IU1, and Bortezomib block the pathway.
(B) Scheme depicting the hierarchy of the ubiquitin cascade. E1 enzymes act at the top of the cascade to
promote charging of multiple E2 enzymes with ubiquitin, which then work with various E3s to promote
substrate ubiquitination, some of which are shown. The NEDD8 E1 (NEDD8-activating enzyme [NAE]),
which is inhibited byMLN4924, works in the sameway to activate UBC12-related E2s, which then transfer
the ubiquitin-like protein NEDD8 to the cullin subunit of CRLs, resulting in their activation. The MDM2 E3 is
inhibited by Nutlin, and the APC/C E3 is inhibited by TAME. CC0651 is a specific inhibitor of CDC34. Two
specific CRL complexes with differing substrate specificity are shown. UBD, ubiquitin-binding domain.their substrates, all of which employ
CDC34, as well as non-CRL-based E3s
that employ distinct E2s, Ceccarelli et al.
pinpointed the likely target of CC0651 as
CDC34 itself. As expected for an inhibitor
of CDC34, CC0651 and related deriva-
tives caused accumulation of p27 and
cyclin E in cells and inhibited proliferation
in a CDC34-dependent manner.
The specificity of CC0651 for human
CDC34 is remarkable. CC0651 inhibited
ubiquitination of a yeast CRL-based E3
in the context of human CDC34, but not
the same E3 in conjunction with yeast
Cdc34p. CC0651 had no ability to inhibit
any other E2/E3 pairs tested and was
even inactive in assays using CDC34B
(UBE2R2), the closest relative of CDC34.
To understand the basis of this selec-1008 Cell 145, June 24, 2011 ª2011 Elseviertivity, Ceccarelli crystallized CDC34 with
CC0651 and found that it binds a pocket
on the opposite side of a central helix
that buttresses the active site. Interest-
ingly, this pocket is not fully formed in
the apoCDC34 structure but becomes
apparent only upon small-molecule bind-
ing, indicative of an induced fit mecha-
nism. CC0651 interacts with its binding
site largely through hydrophobic interac-
tions plus a single hydrogen bond. To-
gether, these interactions help CC0651
inhibit hCDC34 with a potency of 1.9 mM.
Whether this binding pocket affords
opportunities for additional interactions
to drive potency into the nanomolar range
is an important question that will impact
the success of CC0651 as a therapeutic
developmental candidate.Inc.Given that CC0651 does not directly
contact the active site of the enzyme,
how does the inhibitor perturb ubiquitin
transfer to substrates? Structural analysis
suggested several possibilities. CC0651
binding to CDC34 caused the helix
bearing the catalytic cysteine to be dis-
placedby 2.0 A˚. In addition, the interaction
surfaces with the donor ubiquitin (to be
discharged from the enzyme) and with a
surface that interacts with E1 and E3
were perturbed (Ceccarelli et al., 2011).
However, biochemical assays revealed
that E1 and E3 interactions remained
intact in the presence of the inhibitor.
Instead, CC0651 specifically perturbed
the ability of CDC34 to promote ubiquitin
transfer and chain formation on sub-
strates, turning its conjugating activity on
itself and free ubiquitin. Though CC0651
is clearly not acting as an active site-
directed inhibitor, a complete understand-
ing of its mechanism will require further
enzymology as well as structural charac-
terization in combination with the ligase
and its substrates.
The last few years have seen signifi-
cant advances in the identification of
small molecules that block various steps
in the UPS, in addition to E1s and the
proteasome. These include inhibitors tar-
geting distinct E3s [CRL1Cdc4p and the
anaphase-promoting complex/cyclosome
(APC/c)], small molecules that block ubiq-
uitin recognition by binding to ubiquitin
chains, inhibitors of USP14 (a negative
regulator of the proteasome), and inhibi-
tors of the p97 ATPase that is involved in
remodeling ubiquitinated proteins to
enable delivery to the proteasome (Fie-
biger et al., 2004; Orlicky et al., 2010;
Zeng et al., 2010; Verma et al., 2004;
Chou et al., 2011; Bedford et al., 2011)
(Figures 1A and 1B). An exciting implica-
tion of the new work is that it might be
possible to target other E2s selectively in
the future. Ceccarelli et al. suggest that
other E2s also have partially preformed
pockets in the same position as found in
CDC34. However, whether these pockets
can breathe in the same way as observed
for CDC34 remains an open question.
Furthermore, if such pockets do indeed
breathe, it remains unclear whether they
differ substantially enough from CDC34
or contain enough structural complexity
to afford development of highly selective
and potent inhibitors. In order to find
them, however, screening of completely
reconstituted ubiquitylation cascades
may be necessary, as simple E1-E2 thio-
ester assays would not have identified
the CDC34 inhibitor found here. The iden-
tification of CC0651 is an exciting finding
that sets the stage for the discovery of
new E2 inhibitors, but only further work
will reveal whether blocking ubiquitylation
in the middle of the pathway will be better
than blocking it at either end.
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The reports by Bonaguidi et al. (in this issue of Cell) and Encinas et al. (in Cell Stem Cell) come to
differing conclusions about whether and how the proliferation of radial glia-like stem cells of the
adult hippocampus impacts their long-term potential for neurogenesis.Adult neurogenesis had remained a foot-
note in neurobiology until the discovery
of neural stem cells in the 1990s, which
offered an explanation of where new
neurons of the adult hippocampus and
olfactory bulb might originate from. It
was later discovered that the stem cells
of the adult neurogenic regions have as-
trocytic properties and a morphology like
radial glia. In the dentate gyrus of the
hippocampus, these cells have a promi-
nent process that branches out into the
molecular layer. The question then arose
of whether and how cells with such elabo-
rate radial morphology would be capable
of self-renewal—not only by asymmetric
division (in which one morphologically
distinct daughter cell would be gener-ated), but also by symmetric division
(which would produce not one but two
new radial cells). Linked to this question
is the important problem of how the type
and rate of self-renewal would affect the
population of stem cells over time. Now,
two reports (in Cell [Bonaguidi et al.,
2011] and Cell Stem Cell [Encinas et al.,
2011]) come to substantially differing
conclusions about the ability of radial
glia-like stem cells in the hippocampus
to self-renew and thus their capacity for
maintaining neurogenic potential through-
out life (Figure 1).
In a meticulous study based on various
transgenic reporter models in mice, Enci-
nas and colleagues show that the radial-
glia like type-1 cells (quiescent neuralprogenitors [QNP] in their nomenclature;
Mignone et al., 2004) divide asymmetri-
cally to give rise to intermediate progenitor
cells (amplifying neural progenitors [ANP],
or type 2 in our nomenclature; Kemper-
mann et al., 2004). The authors never
observed symmetric division, and over
time, the QNP cells disappear from the
subgranular zone of the dentate gyrus by
differentiating into astrocytes, thereby
drying out the source for more new
neurons (Encinas et al., 2011). In the study
byBonaguidi and colleagues, published in
this issue, the authors use transgenicmice
to induce sparse labeling of precursor
cells (including the amazingly sophisti-
cated two-color MADM reporter; Zong
et al., 2005) to address a similar question5, June 24, 2011 ª2011 Elsevier Inc. 1009
